The medication indazole chloride seems to help in multiple sclerosis.
Many with multiple sclerosis (MS) have likely never heard of experimental autoimmune encephalomyelitis (EAE), although some may know of it as the “mouse model” of MS. Trying out potential MS treatments on mice with EAE is the customary first step in drug research.
If a drug works on EAE, it may be worth a go at testing in humans.
A report published in May in Proceedings of the National Academy of Sciences has shown some possible progress in not the treatment of multiple sclerosis, as disease-modifying drugs do, but in the reversal of damage done by the disease.
The study reported on the drug compound indazole chloride, which stimulates an estrogen receptor in the body. The drug is attractive for a number of reasons, including that it does not produce the negative side effects of estrogen therapy.
While apparent success in EAE does not always cross over as an effective therapy in MS, researchers are intrigued by the results of the indazole chloride study, most of all because it isn’t the only medication in its class that might be effective.
In fact, the study’s authors are screening chemically similar analogs of indazole chloride for more efficacious and safer therapy, and they’re hopeful enough to file for provisional patents for some of these analogs.
“It’s quite possible we may find an analog far superior to indazole chloride,” said Seema Tiwari-Woodruff, an associate professor of biomedical sciences at the University of California in Riverside.
‘Good’ Inflammation Allows for Myelin to Be Replaced
According to the findings, it’s a “good” kind of inflammation, particularly in damaged oligodendrocytes — the myelin-producing cells often damaged during an MS attack — that allows for myelin to be replaced and axon tissue to be preserved. The net effect may be a reversal of disability burden in people with multiple sclerosis.
This study wouldn’t be classed as a drug trial. Its aim is more to understand how drugs like this work, in order to ascertain their potential as treatment.
|Read on: “Good Inflammation” in Multiple Sclerosis … Who Knew?|